Education
About Us
Working with TipRanks
Follow Us
Prostatype Genomics AB (SE:PROGEN)
:PROGEN
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.28 - kr3.56
Previous CloseN/A
Volume7.01K
Average Volume (3M)300.11K
Market Cap
kr56.11M
Enterprise Valuekr22.22M
Total Cash (Recent Filing)kr12.93M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding59,189,320
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityZero reported debt in 2025 materially reduces solvency risk and preserves financing optionality while losses continue. This structural low-leverage profile gives management time to execute commercialization or raise equity without immediate debt servicing pressure, supporting operational flexibility.
Differentiated Diagnostic OfferingA focused prostate-cancer prognostic test that integrates molecular biomarkers with clinical data provides durable clinical differentiation. That product specialization supports defensible positioning in oncology decision support, repeat per-test revenue potential, and clearer commercial value propositions to clinicians and labs over time.
Improving Cash Burn And Gross-level ProgressMaterial reduction in cash burn in 2025 shows operational progress and improves runway relative to prior years. Combined with a prior modest gross profit in 2024, this trend suggests unit-level economics can improve with scale, lowering long-term external financing need if growth resumes steadily.
Bears Say
Persistent Deep Operating LossesSeverely negative margins indicate the current cost structure far exceeds revenue, making profitability distant without substantial revenue scale or cost restructuring. Persistent large losses erode equity, constrain strategic options, and increase reliance on capital raises that can dilute shareholders over time.
Very Small, Volatile Revenue BaseDeclining, inconsistent revenue undermines the company's ability to absorb fixed costs and demonstrates uncertain market adoption. A small, volatile top line limits scalability of positive unit economics and elevates execution risk for commercial expansion and sustained margin improvement.
Negative Operating And Free Cash FlowChronic negative operating and free cash flow mean the business depends on external financing to fund operations and growth. Over time this restricts strategic flexibility, risks funding shortfalls in adverse markets, and can force dilutive equity raises or unfavorable financing terms.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.28 and its highest was kr3.56 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr56.11M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 13, 2026 which is in 149 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -kr0.397 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.397.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.397 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.907%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision medicine by providing innovative genomic solutions that help clinicians make informed decisions regarding patient management and personalized treatment plans. PROGEN's core product is its proprietary genomic test, which analyzes tumor characteristics to predict disease progression and guide therapeutic choices for prostate cancer patients.